In a multicenter study assessing biomarker prevalence in stage IV small bowel adenocarcinoma (SBA), HER3 expression was detected in 40% of tumors analyzed. The study examined 26 patients to evaluate HER2, HER3, and mismatch repair (MMR) proteins, revealing HER2 positivity in 8% and MMR deficiency in 12%. Notably, gene mutations were not assessed, and the study highlighted a minimal overlap among biomarkers. Variability in biomarker expressions was noted between primary tumors and metastases, underscoring the need for detailed molecular characterization in SBA.
Newsletters
Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.